Kompenzují nové léky vliv cytogenetických negativních prognostických markerů u pacientů s mnohočetným myelomem?

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?
Authors

ZAORALOVÁ Romana GREŠLIKOVÁ Henrieta FILKOVÁ Hana NĚMEC Pavel KUGLÍK Petr OLTOVÁ Alexandra POUR Luděk KŘIVANOVÁ Andrea KREJČÍ Marta ADAM Zdeněk SMEJKALOVÁ Jana HÁJEK Roman

Year of publication 2007
Type Article in Proceedings
Conference Sborník abstrakt, XXI. Olomoucké hematologické dny s mezinárodní účastí
MU Faculty or unit

Faculty of Medicine

Citation
Field Genetics and molecular biology
Keywords multiple myeloma; "new drugs"; cytogenetics; cIg FISH
Description In our study, we have concentrated on four aberrations in multiple myeloma (MM) malignant plasma cells: deletions of tumor suppressor genes RB (locus 13q14) and p53 (17q13), translocation involving IGH gene t(4;14), and actually focused amplification of CKS1B gene in 1q21 locus. All of these aberrations are known as negative prognostic factors in patients (pts) treated by conventional therapy or stem cell transplantation. The aim of this study is to show if these selected aberrations act as negative prognostic factors also in patients treated by Velcade or by thalidomide, new drugs used in relapsed patients. In our group of patients, no one of monitored aberrations seems to have any impact, neither positive nor negative, on efficiency of used treatment. It is possible that new drugs, Velcade and thalidomide, antagonize the impact of cytogenetic negative prognostic factors in relapsed patients with MM.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.